Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection

Author:

Karismananda 1ORCID,Hasyim Ammar Abdurrahman2ORCID,Sakamoto Akihiko2ORCID,Yamagata Kyouhei2,Zainal Kartika Hardianti2,Suparman Desi Dwirosalia Ningsih3,Yustisia Ika14ORCID,Hardjo Marhaen14,Kadir Syahrijuita14,Iyori Mitsuhiro5ORCID,Yoshida Shigeto2,Yusuf Yenni6ORCID

Affiliation:

1. Master Program of Biomedical Science, Graduate School of Hasanuddin University, Makassar 90245, Indonesia

2. Laboratory of Vaccinology and Applied Immunology, Kanazawa University, Kanazawa 920-1192, Japan

3. Department of Biochemistry, Faculty of Medicine, Bosowa University, Makassar 90232, Indonesia

4. Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia

5. Research Institute of Pharmaceutical Sciences, Musashino University, Nishitokyo 202-8585, Japan

6. Department of Parasitology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia

Abstract

In the post-pandemic era, evaluating long-term immunity against COVID-19 has become increasingly critical, particularly in light of continuous SARS-CoV-2 mutations. This study aimed to assess the long-term humoral immune response in sera collected in Makassar. We measured anti-RBD IgG levels and neutralization capacity (NC) against both the Wild-Type (WT) Wuhan-Hu and Omicron XBB.1.5 variants across groups of COVID-19-vaccinated individuals with no booster (NB), single booster (SB), and double booster (DB). The mean durations since the last vaccination were 25.11 months, 19.24 months, and 16.9 months for the NB, SB, and DB group, respectively. Additionally, we evaluated the effect of breakthrough infection (BTI) history, with a mean duration since the last confirmed infection of 21.72 months. Our findings indicate fair long-term WT antibody (Ab) titers, with the DB group showing a significantly higher level than the other groups. Similarly, the DB group demonstrated the highest anti-Omicron XBB.1.5 Ab titer, yet it was insignificantly different from the other groups. Although the level of anti-WT Ab titers was moderate, we observed near-complete (96–97%) long-term neutralization against the WT pseudo-virus for all groups. There was a slight decrease in NC against Omicron XBB.1.5 compared to the WT among all groups, as DB group, SB group, and NB group showed 80.71 ± 3.9%, 74.29 ± 6.7%, and 67.2 ± 6.3% neutralization activity, respectively. A breakdown analysis based on infection and vaccine status showed that booster doses increase the NC against XBB.1.5, particularly in individuals without BTI. Individuals with BTI demonstrate a better NC compared to their counterpart uninfected individuals with the same number of booster doses. Our findings suggest that long-term immunity against SARS-CoV-2 persists and is effective against the mutant variant. Booster doses enhance the NC, especially among uninfected individuals.

Funder

International Collaboration Research (I-CORE) Program, Equity WCU LPDP-Institute of Research and Community Services (LPPM), Hasanuddin University

Indonesian Directorate General of Higher Education (DGHE) Japan Society for the Promotion of Science

Grant-in-Aid for Scientific Research©

Publisher

MDPI AG

Reference53 articles.

1. World Health Organization (2024, March 13). Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. Available online: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.

2. (2024, March 13). COVID-19 Epidemiological Update. Available online: https://www.who.int/publications/m/item/covid-19-epidemiological-update---22-december-2023.

3. Symptoms and signs of long COVID: A rapid review and meta-analysis;Healey;J. Glob. Health,2022

4. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection;Lau;eClinicalMedicine,2021

5. SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022;Bloomfield;Emerg. Infect. Dis. J.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3